Navigation Links
iCo Therapeutics Closes $1.3 Million Private Placement
Date:2/9/2009

VANCOUVER, Feb. 9 /PRNewswire-FirstCall/ - iCo Therapeutics Inc. (TSX-V: ICO) is pleased to announce the completion of a $1,292,500 non-brokered private placement. This financing provides the company with sufficient capital to develop iCo-007 through to the completion of the Phase 1 clinical trial. iCo-007 is targeting the treatment of Diabetic Macular Edema. The balance of funds will provide the company with additional working capital. iCo's partner Isis Pharmaceuticals Inc., (NASDAQ: ISIS), participated as a lead investor in the financing, along with select insiders and existing shareholders.

"We are pleased to be able to invest in the advancement of iCo-007, a promising drug in our pipeline being developed with the ocular disease expertise of our partners at iCo," said B. Lynne Parshall, COO and CFO of Isis Pharmaceuticals. "This funding will help move iCo-007 to a key value inflection point by supporting completion of the ongoing study in patients with diffuse macular edema. iCo-007 is a product of our satellite company strategy to exploit antisense technology beyond our core areas of focus to provide new treatment options in a broad range of diseases. With the benefit of our strong financial position, strengthening our pipeline in a variety of ways is a key strategic imperative. This transaction represents one step toward achieving that goal."

The private placement represents 6,462,500 common shares and 3,231,250 million warrants. Each warrant will entitle the holder, on exercise, to purchase one additional Common Share at a price of $0.30 at any time prior to the date 12 months following the closing date. The closing of the first tranche of this placement, in the amount of $582,750, was announced on January 30th, 2009.

A finder's fee of 7% will be payable to certain arm's length third parties with respect to a portion of the private placement. All securities issued in the private placement are subject to a four month hold period. The private placement is subject to regulatory approval, including the approval of the TSX Venture Exchange.

About iCo Therapeutics

iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. iCo has exclusive worldwide rights to three products, iCo-007, in Phase I for the treatment of Diabetic Macular Edema, iCo-008, a product with Phase II clinical history to be developed for severe ocular allergies, and iCo-009, an oral formulation of Amphotericin B for sight and life - threatening diseases. iCo-009 also represents a new drug delivery technology with the potential to reprofile other parenteral administered drugs to the oral route of administration. iCo Therapeutics trades on the TSX-Venture exchange under the symbol "ICO". For more information, visit the company website at: www.icotherapeutics.com

    No regulatory authority has approved or disapproved the content of this
    release. The TSX Venture Exchange does not accept responsibility for the
    adequacy or accuracy of this release.

Forward Looking Statements

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo Therapeutics' current beliefs as well as assumptions made by and information currently available to iCo Therapeutics and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo Therapeutics in its public securities filings; actual events may differ materially from current expectations. iCo Therapeutics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE iCo Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) BIO CEO Presentation to be Webcast
2. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
3. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
4. Cell Therapeutics Exchanges 83% of Remaining Convertible Preferred Stock Into New Non-dividend Bearing, Non-redeemable Convertible Preferred Stock With Conversion Price of $0.14 per Share
5. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
6. Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
7. Omnitura Therapeutics Announces Private Placement Financing
8. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
9. Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc.
10. CV Therapeutics Statement on Unsolicited Proposal From Astellas
11. Cell Therapeutics Receives Additional NASDAQ Notification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... San Diego, CA (PRWEB) , ... August 15, ... ... science company pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces the ... reduces the number of steps needed to gain kinetic binding data for a ...
(Date:8/15/2017)... NY (PRWEB) , ... August 15, 2017 , ... ... first time on Immuno-Oncology 360° (IO360°) programming through a series of upcoming panels and ... held February 7-9, 2018, at The Roosevelt Hotel in New York City. , “With ...
(Date:8/14/2017)... ... 2017 , ... Opal Kelly, a leading producer of powerful ... the release of SYZYGY™, a new open standard for connecting high-performance peripherals to ... low cost, low pin-count, high-performance connectivity solution between FPGAs and single-purpose hardware peripherals. ...
(Date:8/11/2017)... ... 2017 , ... Algenist continues to disrupt the skincare industry with today’s debut ... , Collagen is the key structural element skin needs to maintain its youthful appearance ... First to market with proprietary collagen water active , ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition ... their offering. ... tracking market to grow at a CAGR of 30.37% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
Breaking Biology News(10 mins):